Join Growin Stock Community!

Korro bio, inc.KRRO.US Overview

US StockHealthcare
(No presentation for KRRO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KRRO AI Insights

KRRO Overall Performance

KRRO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KRRO Recent Performance

-4.04%

Korro bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

KRRO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KRRO Key Information

KRRO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KRRO Profile

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Price of KRRO

KRRO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KRRO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
15.50
PB Ratio
1.15
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1199.53%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
15.50
PB Ratio
1.15
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1199.53%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
  • When is KRRO's latest earnings report released?

    The most recent financial report for Korro bio, inc. (KRRO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KRRO's short-term business performance and financial health. For the latest updates on KRRO's earnings releases, visit this page regularly.

  • What is the operating profit of KRRO?

    According to the latest financial report, Korro bio, inc. (KRRO) reported an Operating Profit of -19.24M with an Operating Margin of -1,764.86% this period, representing a growth of 17.41% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is KRRO's revenue growth?

    In the latest financial report, Korro bio, inc. (KRRO) announced revenue of 1.09M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does KRRO have?

    As of the end of the reporting period, Korro bio, inc. (KRRO) had total debt of 44.67M, with a debt ratio of 0.28. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KRRO have?

    At the end of the period, Korro bio, inc. (KRRO) held Total Cash and Cash Equivalents of 24.16M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does KRRO go with three margins increasing?

    In the latest report, Korro bio, inc. (KRRO) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,764.86%%, and net margin of -1,657%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess KRRO's profit trajectory and future growth potential.

  • Is KRRO's EPS continuing to grow?

    According to the past four quarterly reports, Korro bio, inc. (KRRO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.92. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KRRO?

    Korro bio, inc. (KRRO)'s Free Cash Flow (FCF) for the period is -17.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 17.26% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.